Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) CEO Sanjiv Patel sold 48,199 shares of the stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $19.58, for a total value of $943,736.42. Following the transaction, the chief executive officer directly owned 615,898 shares of the company’s stock, valued at approximately $12,059,282.84. The trade was a 7.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Relay Therapeutics Stock Down 0.6%
Relay Therapeutics stock traded down $0.11 during midday trading on Wednesday, hitting $19.63. The company’s stock had a trading volume of 4,272,836 shares, compared to its average volume of 3,411,490. Relay Therapeutics, Inc. has a 12 month low of $3.03 and a 12 month high of $20.20. The company has a market capitalization of $3.76 billion, a PE ratio of -12.50 and a beta of 1.67. The stock’s 50-day moving average price is $14.91 and its 200-day moving average price is $11.72.
Relay Therapeutics (NASDAQ:RLAY – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The firm had revenue of $3.00 million for the quarter, compared to the consensus estimate of $5.58 million. As a group, equities analysts anticipate that Relay Therapeutics, Inc. will post -1.55 EPS for the current year.
Institutional Inflows and Outflows
Analyst Ratings Changes
A number of brokerages recently issued reports on RLAY. The Goldman Sachs Group lifted their target price on Relay Therapeutics from $13.00 to $22.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Guggenheim lifted their price target on Relay Therapeutics from $22.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, May 26th. JonesTrading raised shares of Relay Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 19th. JPMorgan Chase & Co. started coverage on shares of Relay Therapeutics in a report on Wednesday. They issued an “overweight” rating and a $28.00 target price for the company. Finally, HC Wainwright boosted their price target on shares of Relay Therapeutics from $25.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, May 26th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $23.73.
Get Our Latest Analysis on Relay Therapeutics
Relay Therapeutics Company Profile
Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.
The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.
Featured Stories
- Five stocks we like better than Relay Therapeutics
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for Relay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
